Ziopharm oncology

Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.

Business Model:

Revenue: $0

Employees: 11-50

Detailed Ziopharm oncology Information

Geographic Data

Ziopharm oncology headquarters map

Address:

City: New York

State: New York

Zip:

Country: United States

Financial Info

Stage:

post ipo equity

Raised Last:

$8M

Raised Total:

$278M

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

Ziopharm Oncology is a biotechnology company employing a novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM&s;s technology platform employs Intrexon Corporation&s;s RheoSwitch Therapeutic System® to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.

Contact Phone:

Contact Email:

Ziopharm oncology went public on 11/11/2005 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
11/11/2005

Ticker Symbol:
ZIOP

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
2/2007 Post-IPO Equity $0 Henderson Global Investors
Essex Woodlands Healthcare Partners
ProQuest Investments
Pinto Technology Ventures
LBI Group
Essex Woodlands Healthcare Partners
Henderson Global Investors
Essex Woodlands Healthcare Partners
ProQuest Investments
Pinto Technology Ventures
LBI Group
Essex Woodlands Healthcare Partners
9/2019 Post-IPO Equity $8.4M
7/2016 Post-IPO Equity $120M
6/2005 Series A $18.1M
11/2010 Grant $733k
11/2022 Post-IPO Equity $15.7M
1/2015 Post-IPO Equity $57.5M
9/2009 Post-IPO Equity $5.1M
5/2006 Post-IPO Equity $0 ProQuest Investments
Pangaea Asset Management
Paramount BioCapital Asset Management
LBI Group
Cycad Group
Emerging Technology Partners
Henderson Global Investors
ProQuest Investments
Pangaea Asset Management
Paramount BioCapital Asset Management
LBI Group
Cycad Group
Emerging Technology Partners
Henderson Global Investors
2/2007 Post-IPO Equity 5 $30.9M Henderson Global Investors
Essex Woodlands Healthcare Partners
ProQuest Investments
Pinto Technology Ventures
LBI Group
Essex Woodlands Healthcare Partners
Henderson Global Investors
Essex Woodlands Healthcare Partners
ProQuest Investments
Pinto Technology Ventures
LBI Group
Essex Woodlands Healthcare Partners
5/2006 Post-IPO Equity 7 $37M ProQuest Investments
Pangaea Asset Management
Paramount BioCapital Asset Management
LBI Group
Cycad Group
ProQuest Investments
Pangaea Asset Management
Paramount BioCapital Asset Management
LBI Group
Cycad Group
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research